Moli1901

06/30/2005 - "Moli1901 is currently in the clinic and has proven to be safe in single dose studies in human volunteers and cystic fibrosis patients by the inhalation route. "
01/01/2004 - "A phase I trial of intranasal Moli1901 for cystic fibrosis."
05/01/2007 - "Inhalation of Moli1901 in patients with cystic fibrosis."
01/01/2011 - "Search terms used included hypertonic saline, inhaled mannitol, denufosol, Moli1901, lancovutide, and cystic fibrosis. "
09/01/2008 - "Duramycin (Moli1901) is being developed for the treatment of reduced mucociliary clearance in cystic fibrosis. "

05/01/2007 - "A phase II, placebo-controlled, double-blinded, single-center, multiple (5 consecutive days), rising-dose (daily dose, 0.5, 1.5, or 2.5 mg of Moli1901) study was conducted to investigate the safety and tolerability of multiple doses of aerosolized inhaled Moli1901 in 24 patients with CF and stable lung disease. "

01/01/2004 - "Neither Moli1901 nor placebo were associated with visible changes such as edema, erythema, drainage, secretions, or ulcer formation. "

02/01/2003 - "6. Prolonged retention of Moli1901 in pulmonary tissue supports its use in the treatment of respiratory diseases."

05/01/2007 - "Moli1901 was well tolerated in all but one CF patient, in whom a transient significant decrease in FEV(1) developed following inhalation, which resolved spontaneously, and in a second patient in whom transient throat numbness developed during drug inhalation. "